JAMPRO
30.8.2021 17:02:10 CEST | Business Wire | Press release
Jamaica’s manufacturing sector has shown resilience through the COVID-19 pandemic, with the country seeing positive developments in industries such as chemicals and cosmetics.
Manufacturers have seized new opportunities to export to markets that have experienced disruptions in their supply chains. This has led to increased production of items like cleaning chemicals, sanitizers, masks, and OTC pharmaceuticals to meet local and international demand. Jamaica expects this manufacturing expansion to contribute significantly to its economic recovery effort in the next 5 years.
These developments support the island’s goal to be a manufacturing leader in the region. Its government has long highlighted the sector as an area for growth as a myriad of possibilities exist, and Jamaica is strategically located to easily access key markets like the United States, the United Kingdom, Canada, CARICOM and Latin America.
Jamaica has one of the most diverse manufacturing sectors in the Caribbean, ranging from large food-based manufacturing giants such as GraceKennedy Limited and Jamaica Producers Group , to a burgeoning “clean beauty” industry with companies like Ettenio and Irie Rock manufacturing hair and skin care for local and international consumers.
The manufacturing of medical devices, electronics, building materials, and product fitting and assembly are other activities taking place on the island. Contract manufacturing is also an emerging area, as companies seek to use the island as their manufacturing and export base. Jamaica benefits from preferential market access to several regions through trade agreements, further strengthening its position as an ideal contract manufacturing location.
Building on this strong manufacturing tradition, Jamaica’s trade and investment promotions agency, JAMPRO , says that the stage is set for more industries to grow, even with constraints created by the pandemic.
President of JAMPRO, Diane Edwards, explained, “Jamaicans are resourceful, innovative, and committed, and because of that our manufacturing sector continues to find new ways to develop products that are in demand. There are difficulties, but there are opportunities, so the government has been working to give this sector the support it needs to thrive during the pandemic.”
At JAMPRO, this assistance has included engaging manufacturers and investors to produce more value-added goods. The organisation has ongoing initiatives that deliver business-matchmaking services, and facilitates the packaging and promotion of investment projects.
In collaboration with the Jamaica Manufacturers and Exporters Association Limited (JMEA), JAMPRO also provides education and awareness around important subjects like incentives, the Special Economic Zone (SEZ) framework, and regional and global trade agreements that are favourable for products manufactured in Jamaica. The aim is to enhance opportunities for persons to do business in the island.
Positive outlook for manufacturing
With recent global trends in nearshore manufacturing and increased consumption of goods, JAMPRO envisages that more manufacturing will be taking place in Jamaica.
Global health and lifestyle trends will fuel the production of high value goods such as Jamaican Black Castor Oil and its derivatives, and cosmetics made with natural ingredients. According to Transparency Market Research (TMR) the global cosmetics ingredients market, valued at US$30 Bn in 2020, is expected to attain a market value of US$51.6 Bn by 2030.
TMR also notes the rising popularity of natural/herbal cosmetics products, as these items are viewed as healthier alternatives. This creates an excellent opportunity for Jamaica, which currently grows several of the ingredients needed to manufacture these goods.
Reflecting on these trends, Berletta Henlon Forrester, Manager of Manufacturing and Mining at JAMPRO, stated, “Entrepreneurs can explore manufacturing beyond food and beverage, and diversify into health & beauty, packaging & paper, and household chemicals. These industries are supported by Jamaica’s capacity to provide an abundance of ingredients such as bamboo, castor, turmeric, aloe vera and cannabis, to name a few .”
To produce the ideal ecosystem for the success of the aforementioned industries, Jamaica is embarking on a National Five-Year Manufacturing Growth Strategy and is executing government reforms to improve the ease of doing business. This combination should foster the growth of manufacturing and strengthen the sector’s overall performance.
Forrester said, “This is the right time for ambitious manufacturers and investors, both large and small, to initiate their strategies towards Jamaica as the location for their manufacturing project . JAMPRO will be available, as always, to provide the necessary guidance and assistance.”
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/ .
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
